• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

paroxysmal nocturnal hemoglobinuria

empaveli
Pharma

Sobi places $300M bet on Empaveli in partnership with Apellis

Sobi will pay partner Apellis $275 million upfront and up to $25 million in potential milestones to reduce its ex-U.S. royalty obligations on Empaveli.
Kevin Dunleavy Jul 1, 2025 11:28am
paroxysmal nocturnal hemoglobinuria PNH

AstraZeneca's rare disease add-on therapy Voydeya scores FDA nod

Apr 1, 2024 11:48am
Roche

Roche's answer to AstraZeneca PNH drugs nabs China nod

Feb 8, 2024 11:02am
AZ

AZ's newest PNH med Voydeya approved in Japan

Jan 19, 2024 11:06am
Novartis building

Novartis gains first FDA approval for touted blood disorder drug

Dec 6, 2023 11:02am
Alexion

AZ's rare disease rising star Ultomiris snags 3rd FDA nod

Apr 28, 2022 9:15am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings